CoChat

Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody

Open access
Vicari, Alain P., Chiodoni, Claudia, Vaure, Céline, Aït-Yahia, Smina, Dercamp, Christophe, Matsos, Fabien, Reynard, Olivier, Taverne, Catherine, Merle, Philippe, Colombo, Mario P., O'Garra, Anne, Trinchieri, Giorgio, Caux, Christophe · 2002 · The Journal of Experimental Medicine

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Progressing tumors in man and mouse are often infiltrated by dendritic cells (DCs). Deficient antitumor immunity could be related to a lack of tumor-associated antigen (TAA) presentation by tumor-infiltrating DCs (TIDCs) or to a functional defect of TIDCs. Here we investigated the phenotype and function of TIDCs in transplantable and transgenic mouse tumor models. Although TIDCs could encompass various known DC subsets, most had an immature phenotype. We observed that TIDCs were able to present TAA in the context of major histocompatibility complex class I but that they were refractory to stimulation with the combination of lipopolysaccharide, interferon gamma, and anti-CD40 antibody. We could revert TIDC paralysis, however, by in vitro or in vivo stimulation with the combination of a CpG immunostimulatory sequence and an anti-interleukin 10 receptor (IL-10R) antibody. CpG or anti-IL-10R alone were inactive in TIDCs, whereas CpG triggered activation in normal DCs. In particular, CpG plus anti-IL-10R enhanced the TAA-specific immune response and triggered de novo IL-12 production. Subsequently, CpG plus anti-IL-10R treatment showed robust antitumor therapeutic activity exceeding by far that of CpG alone, and elicited antitumor immune memory.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20020732

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. TIDCs may express diverse phenotypes but are immature in their majority. (A) DCs were enriched from the indicated solid tumors and analyzed for the expression of CD11c, CD11b, CD8α, and B220 by flow cytometry (log scale). (B) DCs were enriched from peripheral lymph node or from the indicated solid tumors and the expression of MHC class II, CD40, and CD86 molecules was analyzed among gated CD11c+ cells (solid line) compared with isotype control (gray histograms) by flow cytometry (log scale). Data are representative of two to five experiments.
Figure 1. TIDCs may express diverse phenotypes but are immature in their majority. (A) DCs were enriched from the indicated solid tumors and analyzed for the expression of CD11c, CD11b, CD8α, and B220 by flow cytometry (log scale). (B) DCs were enriched from peripheral lymph node or from the indicated solid tumors and the expression of MHC class II, CD40, and CD86 molecules was analyzed among gated CD11c+ cells (solid line) compared with isotype control (gray histograms) by flow cytometry (log scale). Data are representative of two to five experiments.CC BY-NC-SA · PubMed Central
Figure 2. TIDCs are not activated by LPS plus IFN-γ plus anti-CD40 stimulation. (A) Control BM-DCs or enriched C26–6CK TIDCs were cultured overnight with medium alone or with the combination of LPS, IFN-γ plus anti-CD40 antagonist antibody. Flow cytometry histograms (log scale) show the expression of MHC class II, CD40, and CD86 among gated CD11c+ cells (solid lines) in unstimulated (top panels) or stimulated (bottom panels) DC populations. The percentage of positive cells was determined by comparison with isotype control (gray histogram) and is indicated in the top right corner of each histogram. Results are representative of more than five experiments. (B) The ability to respond to LPS plus IFN-γ and anti-CD40 activation was analyzed by measuring IL-12p70 levels in 18 h culture supernatants in various DC populations: DCs isolated from C26–6CK tumors or axillary draining lymph nodes from the same tumor-bearing animals; DCs enriched from hepatocarcinoma developing in x/myc transgenic mice or from normal liver; BM-DCs cultured in the presence or absence of supernatant from C26 tumors. ELISA results are expressed as the mean concentration ± SEM of triplicate cultures. Similar results were obtained in two to five experiments, depending upon the conditions tested.
Figure 2. TIDCs are not activated by LPS plus IFN-γ plus anti-CD40 stimulation. (A) Control BM-DCs or enriched C26–6CK TIDCs were cultured overnight with medium alone or with the combination of LPS, IFN-γ plus anti-CD40 antagonist antibody. Flow cytometry histograms (log scale) show the expression of MHC class II, CD40, and CD86 among gated CD11c+ cells (solid lines) in unstimulated (top panels) or stimulated (bottom panels) DC populations. The percentage of positive cells was determined by comparison with isotype control (gray histogram) and is indicated in the top right corner of each histogram. Results are representative of more than five experiments. (B) The ability to respond to LPS plus IFN-γ and anti-CD40 activation was analyzed by measuring IL-12p70 levels in 18 h culture supernatants in various DC populations: DCs isolated from C26–6CK tumors or axillary draining lymph nodes from the same tumor-bearing animals; DCs enriched from hepatocarcinoma developing in x/myc transgenic mice or from normal liver; BM-DCs cultured in the presence or absence of supernatant from C26 tumors. ELISA results are expressed as the mean concentration ± SEM of triplicate cultures. Similar results were obtained in two to five experiments, depending upon the conditions tested.CC BY-NC-SA · PubMed Central
Figure 3. Combination of CpG 1668 and anti–IL-10R antibody overcome TIDC paralysis in vitro. (A and B) BM-DCs and TIDCs enriched from C26–6CK tumors were activated overnight with either LPS, IFN-γ, and anti-CD40 (white bars), or CpG 1668 (black bars) in the presence (anti–IL-10R) or absence (none) of anti–IL-10R antibody. Culture supernatants were assayed for IL-12p70 and TNFα content. Results are expressed as the mean concentration ± SEM of triplicate cultures and are representative of more than three experiments. (C) Mixed leukocyte reaction. Irradiated populations of enriched TIDCs, previously activated overnight with none (□), CpG 1668 (○), CpG plus anti–IL-10R (▪), LPS plus IFN-γ plus anti-CD40 (•), or anti–IL-10R plus LPS plus IFN-γ plus anti-CD40 (♦), were cultured with allogeneic purified T cells. Proliferation is expressed as the mean cpm incorporation ± SEM for triplicates.
Figure 3. Combination of CpG 1668 and anti–IL-10R antibody overcome TIDC paralysis in vitro. (A and B) BM-DCs and TIDCs enriched from C26–6CK tumors were activated overnight with either LPS, IFN-γ, and anti-CD40 (white bars), or CpG 1668 (black bars) in the presence (anti–IL-10R) or absence (none) of anti–IL-10R antibody. Culture supernatants were assayed for IL-12p70 and TNFα content. Results are expressed as the mean concentration ± SEM of triplicate cultures and are representative of more than three experiments. (C) Mixed leukocyte reaction. Irradiated populations of enriched TIDCs, previously activated overnight with none (□), CpG 1668 (○), CpG plus anti–IL-10R (▪), LPS plus IFN-γ plus anti-CD40 (•), or anti–IL-10R plus LPS plus IFN-γ plus anti-CD40 (♦), were cultured with allogeneic purified T cells. Proliferation is expressed as the mean cpm incorporation ± SEM for triplicates.CC BY-NC-SA · PubMed Central
Figure 4. CpG 1668 plus anti–IL-10R activates tumor-infiltrating DCs in vivo. Mice bearing C26–6CK tumors were injected intratumorally with 5 μg CpG 1668 or control GpG sequence and/or intraperitoneally with 250 μg anti–IL-10R or isotype control antibody. 2 h after injection, mice were killed, and TIDCs enriched and stained for intracellular IL-12 p40/p70 and surface CD11c. The percentage of IL-12–positive cells among CD11c-enriched TIDCs was determined by comparison with isotype control and is indicated in the top right corner.
Figure 4. CpG 1668 plus anti–IL-10R activates tumor-infiltrating DCs in vivo. Mice bearing C26–6CK tumors were injected intratumorally with 5 μg CpG 1668 or control GpG sequence and/or intraperitoneally with 250 μg anti–IL-10R or isotype control antibody. 2 h after injection, mice were killed, and TIDCs enriched and stained for intracellular IL-12 p40/p70 and surface CD11c. The percentage of IL-12–positive cells among CD11c-enriched TIDCs was determined by comparison with isotype control and is indicated in the top right corner.CC BY-NC-SA · PubMed Central
Figure 5. Induction of tumor antigen–specific immune responses by TIDCs and modulation by CpG plus anti–IL-10R. (A) TIDC cross-present tumor antigen–derived peptides to T cells. The ability of TIDCs from C26–6CK tumors grown in H-2d × H-2b F1 mice to present tumor-derived antigenic peptides was assessed by measuring the secretion of IFN-γ by the CTL clone E/88 (H-2d CTL, white bars) and CTL cell line TG905 (H-2b CTL, black bars). Positive controls consisted of DCs enriched from H-2d × H-2b spleens (APC) and pulsed with the relevant peptide(s) as well as MCA38 H-2b and C26 H-2d cell lines which both express the antigen. (B and C) TIDCs stimulated with CpG 1668 plus anti–IL-10R induce tumor-associated antigen MHC class I–restricted responses in vivo. TIDCs enriched from C26–6CK tumors were cultured overnight with medium alone (TIDC) or CpG 1668 plus anti–IL-10R antibody (TIDC + CpG + a-IL10R), then injected intracutaneously into naive mice. Controls consisted of uninjected mice (negative control) or mice injected with irradiated C26 cells (irrad. C26). Mice were killed 5 d after injection. Experiments were performed with organs pooled from three naive mice and similar results obtained in two separate experiments. (B) Spleens from injected animals were cultured with irradiated C26 cells and IL-2 and cytotoxicity measured against P815 H-2d target cells, alone (white bars) or loaded with the AH-1 antigenic peptide of C26 (black bars). Results are expressed as the mean cytotoxicity ± SEM per triplicate wells at an effector/target ratio of 1:100. (C) Total cell suspensions from pooled draining popliteal lymph nodes were analyzed for IFN-γ–producing cells after overnight culture without (white bar) or with (black bar) AH-1 peptide. Results are expressed as the mean number of spots ± SD for six different wells.
Figure 5. Induction of tumor antigen–specific immune responses by TIDCs and modulation by CpG plus anti–IL-10R. (A) TIDC cross-present tumor antigen–derived peptides to T cells. The ability of TIDCs from C26–6CK tumors grown in H-2d × H-2b F1 mice to present tumor-derived antigenic peptides was assessed by measuring the secretion of IFN-γ by the CTL clone E/88 (H-2d CTL, white bars) and CTL cell line TG905 (H-2b CTL, black bars). Positive controls consisted of DCs enriched from H-2d × H-2b spleens (APC) and pulsed with the relevant peptide(s) as well as MCA38 H-2b and C26 H-2d cell lines which both express the antigen. (B and C) TIDCs stimulated with CpG 1668 plus anti–IL-10R induce tumor-associated antigen MHC class I–restricted responses in vivo. TIDCs enriched from C26–6CK tumors were cultured overnight with medium alone (TIDC) or CpG 1668 plus anti–IL-10R antibody (TIDC + CpG + a-IL10R), then injected intracutaneously into naive mice. Controls consisted of uninjected mice (negative control) or mice injected with irradiated C26 cells (irrad. C26). Mice were killed 5 d after injection. Experiments were performed with organs pooled from three naive mice and similar results obtained in two separate experiments. (B) Spleens from injected animals were cultured with irradiated C26 cells and IL-2 and cytotoxicity measured against P815 H-2d target cells, alone (white bars) or loaded with the AH-1 antigenic peptide of C26 (black bars). Results are expressed as the mean cytotoxicity ± SEM per triplicate wells at an effector/target ratio of 1:100. (C) Total cell suspensions from pooled draining popliteal lymph nodes were analyzed for IFN-γ–producing cells after overnight culture without (white bar) or with (black bar) AH-1 peptide. Results are expressed as the mean number of spots ± SD for six different wells.CC BY-NC-SA · PubMed Central
Figure 6. DCs from various transplantable or transgene-induced tumors are refractory to activation with LPS, IFN-γ plus anti-CD40 but not with CpG 1668 plus anti–IL-10R. The ability of TIDC populations enriched from the indicated tumors to produce IL-12 in response to LPS plus IFN-γ and anti-CD40 or CpG 1668 plus anti–IL-10R was analyzed: (A) by intracellular staining for IL-12p40/p70 together with surface CD11c staining (log scale), percentages of CD11c+ cells expressing intracellular IL-12 are indicated in the top right quadrant; (B) by measuring IL-12 p70 levels in TIDC culture supernatant by ELISA. Results (log scale) are expressed as the mean concentration ± SEM from triplicate cultures.
Figure 6. DCs from various transplantable or transgene-induced tumors are refractory to activation with LPS, IFN-γ plus anti-CD40 but not with CpG 1668 plus anti–IL-10R. The ability of TIDC populations enriched from the indicated tumors to produce IL-12 in response to LPS plus IFN-γ and anti-CD40 or CpG 1668 plus anti–IL-10R was analyzed: (A) by intracellular staining for IL-12p40/p70 together with surface CD11c staining (log scale), percentages of CD11c+ cells expressing intracellular IL-12 are indicated in the top right quadrant; (B) by measuring IL-12 p70 levels in TIDC culture supernatant by ELISA. Results (log scale) are expressed as the mean concentration ± SEM from triplicate cultures.CC BY-NC-SA · PubMed Central
Figure 7. Treatment with CpG 1668 plus anti–IL-10R induces tumor rejection. Groups of seven mice were injected subcutaneously at day 0 with 5 × 104 C26 (A) or B16F0 (B) tumor cells. Mice were treated at day 7, 14, and 21 (arrows) with control antibody, 5 μg CpG 1668 injected intratumorally, 250 μg anti–IL-10R antibody intraperitoneally, or CpG plus anti–IL-10R. Tumor incidence and survival were monitored in all groups for the indicated times.
Figure 7. Treatment with CpG 1668 plus anti–IL-10R induces tumor rejection. Groups of seven mice were injected subcutaneously at day 0 with 5 × 104 C26 (A) or B16F0 (B) tumor cells. Mice were treated at day 7, 14, and 21 (arrows) with control antibody, 5 μg CpG 1668 injected intratumorally, 250 μg anti–IL-10R antibody intraperitoneally, or CpG plus anti–IL-10R. Tumor incidence and survival were monitored in all groups for the indicated times.CC BY-NC-SA · PubMed Central
Figure 8. Treatment with CpG 1668 plus anti–IL-10R induces T cell and NK cell–mediated tumor rejection as well as antitumor immune memory. Groups of seven mice were injected subcutaneously at day 0 with 5 × 104 C26 tumor cells. (A) Mice were treated at day 7, 14, and 21 (arrows) with control or 5 μg CpG 1668 injected intratumorally plus 250 μg anti–IL-10R antibody intraperitoneally. Indicated groups of mice receiving anti–IL-10R plus CpG were further treated with anti-CD4, anti-CD8, or Asialo-GM1 depleting antibodies as described in Materials and Methods. (B) Immunodeficient SCID mice were treated at day 7, 14, and 21 (arrows) with control, 5 μg CpG 1668 injected intratumorally, 250 μg anti–IL-10R antibody intraperitoneally or CpG plus anti–IL-10R. (C) Mice were injected intratumorally at day 7, 14, and 21 (arrows) with 5 × 104 enriched tumor-infiltrating DCs activated for 2 h in vitro with none, LPS plus anti-CD40 plus anti–IL-10R, or CpG plus anti–IL-10R, as well as intraperitoneally with 250 μg anti–IL-10R antibody. (D) Mice treated with CpG plus anti–IL-10R that had rejected a C26 tumor inoculated at day 0 (n = 12) were rechallenged at day 45 with 5 × 104 C26 cells in the contralateral flank and compared naive mice challenged with the same inoculum. Tumor incidence and survival were monitored in all groups for the indicated times.
Figure 8. Treatment with CpG 1668 plus anti–IL-10R induces T cell and NK cell–mediated tumor rejection as well as antitumor immune memory. Groups of seven mice were injected subcutaneously at day 0 with 5 × 104 C26 tumor cells. (A) Mice were treated at day 7, 14, and 21 (arrows) with control or 5 μg CpG 1668 injected intratumorally plus 250 μg anti–IL-10R antibody intraperitoneally. Indicated groups of mice receiving anti–IL-10R plus CpG were further treated with anti-CD4, anti-CD8, or Asialo-GM1 depleting antibodies as described in Materials and Methods. (B) Immunodeficient SCID mice were treated at day 7, 14, and 21 (arrows) with control, 5 μg CpG 1668 injected intratumorally, 250 μg anti–IL-10R antibody intraperitoneally or CpG plus anti–IL-10R. (C) Mice were injected intratumorally at day 7, 14, and 21 (arrows) with 5 × 104 enriched tumor-infiltrating DCs activated for 2 h in vitro with none, LPS plus anti-CD40 plus anti–IL-10R, or CpG plus anti–IL-10R, as well as intraperitoneally with 250 μg anti–IL-10R antibody. (D) Mice treated with CpG plus anti–IL-10R that had rejected a C26 tumor inoculated at day 0 (n = 12) were rechallenged at day 45 with 5 × 104 C26 cells in the contralateral flank and compared naive mice challenged with the same inoculum. Tumor incidence and survival were monitored in all groups for the indicated times.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

Items 101–200 of 351

Metadata

Authors
Vicari, A. P., Chiodoni, C., Vaure, C., Aït-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M. P., O'Garra, A., Trinchieri, G., & Caux, C.
Affiliations
  • 1Schering-Plough Laboratory for Immunological Research, 69571 Dardilly, France
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
  • Inserm (FR)
  • 4DNAX Research Institute, Palo Alto, CA 94304
Venue
The Journal of Experimental Medicine
Published
2002-08-19
Volume
196
Issue
4
Pages
541-549
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2156592930
Cited by
343
References
35
Citations by year
2026: 4 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 10 · 2021: 8 · 2020: 8 · 2019: 14 · 2018: 7 · 2017: 19 · 2016: 12 · 2015: 17 · 2014: 21 · 2013: 21 · 2012: 21
FWCI
4.39
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
tumor-infiltrating dendritic cells, MHC class I, DC maturation, IL-12, antitumor immunity, antitumor immune memory, transplantable tumors
MeSH terms
Adjuvants, Immunologic, Animals, Antibodies, Monoclonal, Dendritic Cells, Female, Immunity, Active, Immunity, Innate, Immunologic Memory, Interferon-gamma, Killer Cells, Natural, Lipopolysaccharides, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Oligodeoxyribonucleotides, Tumor Cells, Cultured, Antigens, Tumor-Associated, Carbohydrate, Mice, SCID, Receptors, Interleukin, CD8-Positive T-Lymphocytes, CpG Islands, CD40 Antigens, Mice, Receptors, Interleukin-10

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.